NCT05110495View on ClinicalTrials.gov

IGF Inhibition With Xentuzumab Prior to Radical Prostatectomy

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

December 17, 2021

Primary Completion Date

March 20, 2023

Study Completion Date

May 27, 2023

Conditions
Prostate Cancer
Interventions
DRUG

Xentuzumab

The study IMP is xentuzumab, a humanised IgG1 monoclonal antibody that neutralises the IGF ligands to inhibit activation of IGF-1R and INSR-A, suppressing IGF-mediated proliferation, invasion and therapy resistance

Trial Locations (1)

OX3 7LE

Churchill Hospital, Oxford University Hospitals, Oxford

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Prostate Cancer UK

OTHER

collaborator

Boehringer Ingelheim

INDUSTRY

lead

University of Oxford

OTHER

NCT05110495 - IGF Inhibition With Xentuzumab Prior to Radical Prostatectomy | Biotech Hunter | Biotech Hunter